🔍

Zenotech Laboratories Ltd (532039)

📊 BSE: 532039 🏢 Pharmaceuticals 📢 Latest filing: 26 Sep 2026 📝 Analysis written: 13 Nov 2025

Latest quarterly results (Q1 FY27)

In its latest reported quarter, Q1 FY27, Zenotech Laboratories' revenue was ₹10.6 Cr (+10.1% year on year, +7.3% on the previous quarter), and net profit ₹-0.5 Cr (against a profit a year earlier); the operating margin was 8.2%.

Q1 FY27 (₹ Cr)	Value	YoY vs Q1 FY26	QoQ
Revenue	₹10.6	+10.1%	+7.3%
Operating profit	₹0.9	-64.8%	+409.4%
Net profit	₹-0.5	to loss	loss narrowed
EPS (₹)	-0.07	to loss	loss narrowed
Operating margin	8.2%	—	—

Full quarterly financials → Results calendar →

📢 Recent Corporate Announcements

Zenotech Shareholders Approve All 37th AGM Resolutions, Including RPT With Sun Pharma

🟡 NEUTRAL ⭐ 3/10

ROUTINE 📅 26 Sep 2026, 12:03 PM

Zenotech Laboratories Limited concluded its 37th Annual General Meeting held on September 25, 2026, passing all three ordinary resolutions with the requisite majority. Key approvals included the adoption of FY26 financial statements, the re-appointment of Director Jignesh Anantray Goradia, and material related-party transactions (RPT) with Sun Pharmaceutical Industries Limited. For the RPT resolution, promoter votes were excluded, and public non-institutional shareholders approved the measure with 78.17% votes in favor and 21.83% against.

All 3 resolutions passed at the 37th AGM held on September 25, 2026
Material Related Party Transaction with Sun Pharma approved with 78.17% (2,23,523 votes) in favor and 21.83% (62,410 votes) against among public votes polled
Overall voter turnout stood at 69.31% of total shares (4,23,00,511 votes polled out of 6,10,30,568 outstanding)
Adoption of FY26 standalone financial statements passed with 99.95% overall approval

💡 Track subsequent quarterly filings to evaluate the financial scale and terms of transactions executed with Sun Pharmaceutical Industries Limited.

Zenotech Lab Schedules 37th AGM for Sep 25, 2026; Seeks ₹200 Cr RPT Approval with Sun Pharma

🟡 NEUTRAL ⭐ 3/10

ROUTINE 📅 28 Aug 2026, 12:56 PM

Zenotech Laboratories Limited has released its FY 2025-26 Annual Report and notice for its 37th Annual General Meeting scheduled for September 25, 2026. The key special business item includes seeking shareholder approval for material related party transactions (RPT) with parent/promoter Sun Pharmaceutical Industries Limited for an aggregate value up to ₹200 Crore. Zenotech primarily manufactures products under a loan licensing arrangement with Sun Pharma. The remote e-voting period runs from September 22 to September 24, 2026, with a cut-off date of September 18, 2026.

37th Annual General Meeting scheduled for Friday, September 25, 2026, at 10:30 AM IST via Video Conferencing
Seeking omnibus approval for material Related Party Transactions with Sun Pharmaceutical Industries Limited up to ₹200 Crore
Cut-off date for e-voting eligibility fixed as Friday, September 18, 2026
Remote e-voting window opens on September 22, 2026 (09:00 AM IST) and closes on September 24, 2026 (05:00 PM IST)

💡 Track the outcome of the AGM voting on September 25, 2026, particularly the approval of the ₹200 Crore RPT limit with Sun Pharma, which forms the operational backbone of the company.

Zenotech Labs Discloses FY26 Annual Report; 37th AGM on Sept 25, Seeks ₹200 Cr RPT Approval

🟡 NEUTRAL ⭐ 3/10

ROUTINE 📅 28 Aug 2026, 12:50 PM

Zenotech Laboratories Limited has published its Annual Report for FY 2025-26 and issued the notice for its 37th Annual General Meeting (AGM) scheduled for September 25, 2026. A key agenda item is seeking shareholder approval for material Related Party Transactions (RPT) with promoter Sun Pharmaceutical Industries Limited up to ₹200 Crore for loan licensing and manufacturing operations. The cut-off date for voting eligibility is September 18, 2026, with remote e-voting running from September 22 to September 24, 2026.

37th AGM scheduled for Friday, September 25, 2026, via Video Conferencing
Seeking omnibus approval for material Related Party Transactions with Sun Pharma up to ₹200 Crore
Remote e-voting window opens September 22, 2026 (9:00 AM) and closes September 24, 2026 (5:00 PM)
Voting eligibility cut-off date fixed as Friday, September 18, 2026

💡 Track shareholder voting outcomes on the ₹200 Crore RPT resolution post the AGM on September 25, 2026, and monitor subsequent operational execution under the Sun Pharma contract manufacturing arrangement.

Zenotech Laboratories Schedules 37th AGM for Sept 25, 2026; Cut-off Date Set as Sept 18, 2026

🟡 NEUTRAL ⭐ 2/10

ROUTINE 📅 22 Aug 2026, 05:33 PM

Zenotech Laboratories Limited has announced that its 37th Annual General Meeting (AGM) will be held on Friday, September 25, 2026, at 10:30 a.m. IST via Video Conferencing. The company has fixed Friday, September 18, 2026, as the cut-off date to determine shareholder eligibility for e-voting and AGM participation. The detailed Annual Report and AGM Notice will be released separately in due course.

37th Annual General Meeting scheduled for September 25, 2026, at 10:30 a.m. IST via Video Conferencing
Cut-off date fixed as September 18, 2026, for voting eligibility and meeting attendance
Filing follows earlier corporate communication dated July 28, 2026
Annual Report and AGM Notice containing resolution details to be released in due course

💡 Shareholders should track the release of the upcoming Annual Report and AGM Notice to evaluate agenda resolutions and operational commentary.

Zenotech Reports Q1 FY27 Net Loss of ₹0.46 Cr as Expenses Outpace 11% Revenue Growth

🔴 NEGATIVE ⭐ 6/10

EARNINGS 📅 28 Jul 2026, 02:47 PM

Zenotech Laboratories reported a net loss of ₹0.46 crore for the quarter ended June 30, 2026, compared to a profit of ₹0.99 crore in the same period last year. While revenue from operations grew 11.1% YoY to ₹9.60 crore, total expenses surged 30.1% YoY to ₹11.65 crore, primarily due to higher employee and other operating costs. The company continues to rely on rental income of ₹1.02 crore from leasing its biotech facility to Sun Pharmaceutical Industries. The 37th Annual General Meeting is scheduled for September 25, 2026.

Revenue from operations increased to ₹9.60 crore from ₹8.64 crore in Q1 FY26.
Total expenses rose significantly to ₹11.65 crore, up from ₹8.95 crore in the year-ago quarter.
Reported a net loss of ₹0.46 crore, a sharp decline from the ₹0.99 crore profit in Q1 FY26.
Other operating income remained steady at ₹1.02 crore, derived from leasing facilities to Sun Pharma.
Employee benefit expenses increased by 39% YoY to ₹4.92 crore.

💡 Monitor the company's ability to contain operating costs, particularly employee expenses, which are currently eroding revenue gains. Investors should look for updates on the utilization of the biotech facility during the AGM on September 25, 2026.

Zenotech Q1 Results: Revenue Up 11% YoY to ₹9.60 Cr, Swings to Net Loss of ₹0.46 Cr

🔴 NEGATIVE ⭐ 6/10

EARNINGS 📅 28 Jul 2026, 02:40 PM

Zenotech Laboratories reported a marginal 11.1% YoY increase in revenue from operations to ₹9.60 crore for Q1 FY27. Despite the revenue growth, the company posted a net loss of ₹0.46 crore, a sharp reversal from the ₹0.99 crore profit recorded in the same quarter last year. This downturn was driven by a 30% surge in total expenses, particularly employee benefit costs which rose 39% YoY. The company continues to rely on rental income of ₹1.02 crore from Sun Pharma for its biotech facility to support its top line.

Revenue from operations increased 11.1% YoY to ₹9.60 crore from ₹8.64 crore.
Total expenses surged 30.1% YoY to ₹11.65 crore, outpacing revenue growth.
Employee benefit expenses rose significantly to ₹4.92 crore compared to ₹3.54 crore in the year-ago period.
Reported a net loss of ₹0.46 crore for the quarter versus a net profit of ₹0.99 crore YoY.
Other operating income of ₹1.02 crore was generated from leasing facilities to Sun Pharmaceutical Industries.

💡 Investors should monitor the company's ability to contain rising operating costs, especially employee and 'other' expenses, which are currently eroding margins. The upcoming Annual General Meeting on September 25, 2026, may provide more clarity on the long-term utilization of its Hyderabad facility.

Zenotech Laboratories Board Meeting on July 28, 2026, to Approve Q1 Results

🟡 NEUTRAL ⭐ 2/10

BOARD_MEETING 📅 13 Jul 2026, 04:33 PM

Zenotech Laboratories has scheduled a board meeting for July 28, 2026, to review and approve the unaudited standalone financial results for the quarter ended June 30, 2026. This is a routine regulatory filing as per SEBI Listing Obligations. The trading window for insiders, which closed on July 1, 2026, will remain shut until July 30, 2026, which is 48 hours after the results are announced. Investors should look for the actual earnings release on the scheduled date to assess the company's performance.

Board meeting scheduled for July 28, 2026, to approve Q1 FY27 results
Financial results pertain to the quarter ended June 30, 2026
Trading window closed from July 1, 2026, until July 30, 2026
Meeting to consider Unaudited Standalone Financial Results

💡 Monitor the company's financial performance on July 28, 2026, specifically focusing on revenue trends and profitability margins compared to previous quarters.

View All 532039 Announcements on Live Market Tracking →